



European Biotechnology

ISSN 2364-2351 | A 60711 | BIOC.COM

Life Sciences and
Industry **Magazine**

Autumn Edition 2022 | Volume 21 | 20 €

Interview

Abivax CEO Hartmut Ehrlich on what's needed to establish new approaches to autoimmune diseases.



FREE EXCERPT

Protein Degraders

Molecular Targeting

Industrial Biotech

Bioengineered bacteria that could help stop climate change

Patent Waiver

How the WTO is corroding the roots of biopharma innovation

CROs & CDMOs

How gene and cell therapies are transforming the pharma market

BIOC.COM

Prep for the future

Novel semi-preparative Supercritical Fluid Chromatography system

Designed in collaboration with the Enabling Technologies Consortium, the award-winning Nexera UC Prep SFC is a next-generation solution to the demand for efficient and robust semi-prep SFC purification in the pharmaceutical, chemical and food industries. Its flexible system configuration in a compact design allows users to overhaul their workflow, reduce inefficiencies and meet a wide range of purification requirements.

High recovery rates

through the patented "LotusStream" gas-liquid separator technology

Maximizes lab resources

with its compact design, green technology and fast dry down times

Streamlined processes

while fitting into pre-existing workflows with the easy-to-use "Prep Solution" software



Biotechnology-driven carbon revolution



DR MICHAEL KÖPKE, is pioneer in Synthetic Biology of carbon-fixing microbes. Michael started his career at the University of Ulm and has over 15 years' or experience in biotech. Since 2009, he is working for LanzaTech, currently as VP of Synthetic Biology. Michael is also an adjunct faculty at Northwestern University and part of the Engineering Biology Research Consortium council. He is an inventor of over 200 patents, has published over 50 scientific articles and is an awardee of the Presidential Green Chemistry Challenge award.

Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations. To achieve our climate goals and mitigate climate disasters, a large-scale, robust, rapid, and sustained effort must be made to re-tool our entire carbon economy. To align with a "Net Zero Path," economies today are investing in innovative carbon transformation technologies that enable a circular carbon economy where carbon is reused rather than wasted.


Aimed to foster that clean energy future, biotechnology is poised to play a major part in a circular carbon economy providing a path to displace products made from petroleum with alternatives from recycled carbon. Biological systems are uniquely suited for this challenge. Life on Earth evolved on transforming CO₂ into more complex building blocks and biology unlike traditional technologies is inherently flexible and capable of processing chaotic input streams. This allows accessing low-cost, regional feedstocks including industrial off-gases, agricultural residues, and municipal waste; CO₂ with the addition of green H₂ can make an unlimited supply of sustainable products. Imagine polyester for a dress made from recycled carbon from a steel mill. This is not science fiction, it's happening commercially today. Global consumer brands are already using recycled carbon chemicals in their supply chain enabled by biotechnology.

As we enter a critical period for energy use and for our climate, we should all take steps to consider how to enable a stronger circular carbon economy. As business leaders, we can use carbon transformation to rethink how we procure, use, and dispose of carbon. And as consumers, we can choose where our carbon comes from. In the quest for innovative technologies, we must ensure they benefit both rural communities and traditional manufacturing centers to support a more sustainable, equitable, and resilient economy.

Carbon transformation technologies offer solutions that can be applied across economic sectors, such as agriculture, industry, and waste management, as an essential strategy to reduce greenhouse gas emissions; meet commitments to reduce fossil imports and support the wider economy. Carbon transformation can address sustainability needs domestically by reducing air pollution, recycling waste, providing clean jobs, generating cleaner burning fuels, and producing low-carbon materials stamped. But we need more industries to adopt the approach. To heal and repair the world takes time. And with innovation and strong partnerships and the support of government leaders, we are ready to make the transition and celebrate a post-pollution future. ■

FREE EXCERPT

COVER STORY



14

The new drug class of degraders and glues

The 2004 Nobel Prize for Chemistry was granted for the discovery of the ubiquitin degradation pathway of proteins, while seminal work in the field happened decades earlier. But only recently have over 15 compounds in a new drug class based on ubiquitination truly entered clinical development. What are known as PROTACs and 'molecular glues' are now driving a dynamic field, and the pharmaceuticals industry is throwing a lot of funding at it. The ability to mark disease-causing protein targets for destruction could soon help treat even 'undruggable' conditions.

INSIGHT EUROPE

- 8 Industry concerned about World Trade Organisation plan to expand COVID-19 patent waiver to diagnostics and med-tech
- 12 European Commission blocks Illumina's US\$8bn acquisition of liquid biopsy leader Grail; CRO survey finds trend towards study decentralisation; ECBF expands company portfolio

ECONOMY

- 14 New drug class of protein degraders advances to clinical stage
- 22 Analyst commentary; News from the floor
- 23 European Biotech Stocks
- 26 Interview: Prof. Dr Hartmut Ehrlich, CEO, Abivax SA, Paris
- 30 Update on clinical trials
- 32 Biopharma partnering is the next financing

- 34 Start-up profile: EpiQMAx GmbH, Martinsried, Germany
- 36 The pharma lab in the era of gene and cell therapies
- 58 Bioenergy and biofuels from carbon dioxide feedstocks

REGIONAL NEWS

- 66 Northern Europe: Sweden, Denmark and Iceland
- 68 Western Europe: France, Belgium, The Netherlands and the UK
- 70 Central Europe: Germany, Switzerland and Austria
- 72 Southern Europe: Italy, Spain and Greece
- 74 Eastern Europe: Poland and the Czech Republic

SCIENCE & TECHNOLOGY

- 75 Sourcing innovation in the life sciences sector
- 76 New cell model drives R&D; Nasal antibody cocktail eliminates SARS-CoV-2 variants
- 77 Speedy DNA extraction from buccal swabs & FFPE samples
- 80 Cool chain: reliable medical-grade refrigerators

PICK & MIX

- 83 News from Biotech Austria, the Swiss Biotech Association and the ECBF
- 88 New products
- 88 Company index
- 89 Events
- 90 Encore

INDUSTRIAL BIOTECH

Solving the gas crisis

Fossil fuel use is driving climate change. Almost 80% of today's anthropogenic CO₂ emissions can be traced back to the burning of oil, coal or natural gas. To help preserve existing infrastructure, bioengineers are working to make combustion in cars, aircraft and power plants CO₂-neutral. We took a look at the most advanced technologies in the field.



INFLAMMATION



26

Final track for Abivax

Paris-based public company Abivax SA has bagged €50m to push development in its promising Phase III candidate obefazimod in autoimmune diseases, starting with ulcerative colitis. We spoke with CEO Hartmut Ehrlich about how despite the cash injection, the trials still face financing challenges.

EDITORIAL

Industrial Biotech

The EU climate change service Copernicus recently determined that in 2022, the months of June, July and August were warmer in Europe than at any time since records began. In addition, August this year was generally much drier than average in Western Europe, and some areas in the eastern part of the continent as well. Few people continue to think we're just living through capricious weather. The climate catastrophe has begun, and industrialised countries are desperately searching for ways to lower dependence on fossil fuels.

Unfortunately, biotechnological solutions are hardly being discussed at all in the current climate and energy crisis, even though it should be clear that our global economy urgently needs to be adapted to the natural cycles of our planet. The best way to do that is to biologise industry. Why aren't decisionmakers talking about it?

A new event aims to remedy the situation: INDUSTRIA BIOTEC, which will take place on 7 October in Berlin. This European convention is dedicated to the most important areas of application and impact of biotechnological solutions in five forums: Nutrition (Food), Energy, Waste, Chemistry and Capital.

In addition, there will be a range of other information and communication offers, such as partnering, a start-up pitch, company presentations, an exhibition and – of course – plenty of opportunities for personal exchange. And all of this at a sensational venue from the 1920s. We look forward to seeing you there!



Andreas Mietzsch
Publisher


SPECIAL

CROs & CDMOs

- 39 Technology expansion
- 40 Interview: Christian Schetter, CSO, Rentschler Biopharma SE
- 44 CRO of the future
- 46 Innovation in drug development
- 48 Bringing virotherapy forward
- 50 Interview: Dimitrios Wagner, Charité
- 53 CB21 R&D: CDMO for endocannabinoids
- 54 Vector BioPharma: the future of gene delivery



Pictures: © AdobeStock/Julialucrea; Abivax SA (right), Gringobio/works (upper left), BIOCOMAG (right)



Previously undruggable tumours could soon be treated with therapies that harness the body's natural clean-up processes.

Breaking down diseased proteins

UBIQUITINATION The Nobel Prize for Chemistry was granted for the discovery of the ubiquitin degradation pathway of proteins back in 2004, while the seminal work in the field happened decades earlier. But only recently have over 15 compounds in a new class based on the mode of action truly entered clinical development, mainly in cancer. What are known as PROTACs and molecular glues are now driving a dynamic research area, and the pharmaceuticals industry has begun to throw serious funding at it.

Fans can storm a football pitch for a couple of different reasons. It might be after the final whistle, or a serious foul, or perhaps a bad call on the part of the referee. In the game of drug development, however, Big Pharma spectators don't leave their seats very often. So when you see them running out onto the field eager to join forces with promising companies, it's a pretty good bet blockbusters won't be far behind.

The pioneering work behind it

That's what's happening for instance in the field of 'targeted protein degradation' (TPD), which has been evolving and maturing since the early 1980s, when Aaron Ciechanover, Avram Hershko and Irwin Rose published studies on ubiquitination that would eventually lead to their jointly-received Nobel Prize. An important milestone along the way was work published by Craig Crews and colleagues in 2001. It described the first hetero-biofunctional degrader – a novel use of the ubiquitin system through external addition that for the first time seemed to put targeted degradation reactions within reach. But it took another decade until Crews was able to move into concrete application and development. He only founded the startup Arvinas in 2013, af-

ter it could be shown that a synthetic protein degrader also works *in vivo*.

At that time, the field was still pretty sparsely populated, and not many spectators were scattered throughout the bleachers. But progress at Arvinas and other firms on the pitch was gradually awakening interest. Interestingly, the startup's first major partnership with Bayer in 2019 was in the agricultural sector, where a joint venture called Oerth Bio was set up to test the functionality and usability of PROTACs in a kind of side-show. After Arvinas launched a clinical trial the same year and started presenting proof-of-concept for their two degrader projects (ARV-471 and ARV-110) in 2020, the field turned into a pretty popular pie. Suddenly, it seemed, everyone wanted a slice.

In the years since, many more companies have brought related projects into the clinic, and a lot more lucrative deals between biotech start-ups and Big Pharma have been struck.

From bench to bedside

By the end of 2022, around 15 degraders will have entered clinical trials, and it's past time to explain how they work. Unlike conventional drugs, which often block the action of a protein by binding to a specific site, targeted degraders

use the cell's natural waste disposal system (in which ubiquitin plays a key role) to remove harmful proteins by marking them up for destruction. The principle could also be applied to treat disease, especially for illnesses previously considered untreatable.

A major advantage with degraders is that they can destroy target proteins that can't be addressed with conventional drugs. There are currently two different classes of protein degraders in use: PROTACs (PROteolysis TARgeting Chimeras), and 'molecular glues' (also called 'molecular glue degraders'). Both utilise small molecules that can pass through barriers in cells. PROTACs are made up of two protein-binding molecules joined together by a linker. One of them binds specifically to the protein targeted for degrading. The second molecule recruits the E3 ubiquitin ligase. It's a special enzyme that can transfer the regulatory protein ubiquitin to other proteins, which marks them up for destruction by the proteasome.

Conventional small-molecule drugs require a defined binding site on the surface of a target protein, but molecular adhesives don't. This opens up a completely new possibility – intervening with proteins that were previously consid-

» Read the full story in the printed issue.



Future energy: Biology strikes back

SYNTHETIC BIOLOGY When it comes to climate change, combustion is the new scourge of humanity. Almost 80% of today's anthropogenic CO₂ emissions can be traced to the burning of fossil fuels. More than a third of all emitted carbon dioxide is due to power generation, while industrial combustion and transport are each responsible for another fifth. Bioengineers are racing to make combustion in automobiles, aircraft and power plants CO₂-neutral while preserving existing infrastructure. It's a tricky path to tread.

In March of this year, Jason Kelly, the CEO and co-founder of the SynBio company Ginkgo BioWorks, posted an astonishing message. "The best time to address climate change was decades ago," he wrote, then asked when the next-best time would be. "Limiting warming to below 1.5°C will require us to reimagine our industrial landscapes to eliminate emissions and to sequester carbon from the atmosphere," he said. "Decarbonising our energy, materials, chemicals, and food production will require massive shifts in how we make stuff." The way forward, according to Kelly, must definitely be rooted in what he sees as the most advanced manufacturing technology on the planet: biology – particularly, synthetic biology. The code of life of microorganisms, enzymes and cell factories will have to be rewritten to produce energy, fuels, chemicals and food without CO₂ emissions. According to Bill Gates, synthetic biology will soon be one of the enabling climate technologies that will create companies that generate trillions of dollars.

In the midst of the current energy crisis, some biotech companies are finally ready to make the old combustion technology – decried as a climate disaster but still a pillar of private and industrial transport – more acceptable. After all, their advanced biofuels already cut CO₂ emis-

sions by 60-90% by harnessing gas fermentation of cellulosic waste or combustion gases from steel mills, oil refineries or aluminum smelters. Even natural gas can now be produced in fermenters with help from pathway-engineered micro-

organisms, without using any agricultural land at all. The tank-or-table debate actually ended long ago. Together with overdue, binding regulations on energy conservation, the widespread use of biotechnology promises a reprieve from annual CO₂ emissions that, according to the International Energy Agency (IEA), doubled globally between 1970 and 2010.



PROF. DR PETER LINDBLAD
Head Microbial Chemistry, Ångström
Laboratory, Univ. of Uppsala, Sweden

? How can SynBio contribute to the mitigation of CO₂ emissions?

! By combining advanced genetic engineering and synthetic biology, we can design microbial cells that are capable of performing entirely new functions. Our team is trying to demonstrate how you can take modified cyanobacteria that produce isoprene and, by using solar energy and photochemistry, get aviation fuel directly.

Carbon-negative manufacture

Using the chemolithotrophic bacterium *Clostridium autoethanogenum* as a chassis strain for AI-supported metabolic pathway engineering, Illinois-based Lanzatec Inc. has established a continuous production process that can produce drop-in biofuels and over 100 commodity chemicals with a negative carbon footprint. The company licences its carbon capture and transformation (CCT) plants under the product brand CarbonSmart™ to industrial customers.

For commercial-scale, next-generation bioethanol production, the company runs two plants in China that convert steel mill combustion gases. Already in pilot-scale seven years ago, the continuously optimised process produced bio-ethanol that emitted 70% less CO₂ than gasoline – a result similar to second-generation cellu-

» Read the full story in the printed issue.

FREE EXCERPT

- 3D Medicines Co. Ltd. (CN) 30
- AB InBev Group (B) 69
- AbbVie Inc. (USA) 16
- Abivax SA (F) 26, 27, 69
- AC Immune SA (CH) 71
- Advent Life Sciences LLP (UK) 85
- Aegean Airlines (GR) 73
- AGC Biologics (USA) 39
- Albumedix (DK) 68
- AllianceBernstein (USA) 22
- Alphamab Oncology (CN) 30
- Alvotect SA (ISL) 67
- AmBev (B) 69
- Amgen Inc. (USA) 16, 18
- Amphista Therapeutics Ltd. (UK) 17, 18
- Amyris Inc. (USA) 60
- Andera LifeSciences Partners (F) 90
- Apex Ventures (AT) 19
- arGEN-X BV (NL/B) 22
- Artcline GmbH (DE) 31
- Arvinas Inc. (USA) 15-18
- Asabys Partners (ES) 73
- AstraZeneca (GB/SE) 16
- Austrian Business Agency** 64, 65
- Avantium NV (NL) 69
- AXA Investment (USA) 67
- Axxam SpA (IT) 72
- Azenta Inc. (USA) 69
- B Medical Systems S.a r.l. (LU)** . . . 13, 69, 80
- Bactlife A/S (DK) 67
- BASF SE (DE) 60, 62, 65
- Bavaria Weed GmbH (DE) 66
- Baxter International (USA) 68
- Bayer AG (DE) 15, 16, 86, 72
- Bilfinger SE (DE) 65
- BIOCOM AG (DE)** 20, 25, 56, 57
- BioEcho Life Sciences GmbH (DE)** 77
- Bioeq AG (CH) 30, 44
- BioFIT 2022 (F)** 61, 75
- Biofrontera AG (DE) 70
- Biofrontera Inc. (USA) 70
- BiolInvent International AB (SE) 67
- Biomerieux (F) 68
- BioNTech SE (DE) 30, 67
- Biosyntia ApS (DK) 12
- Blueprint Medicines (USA) 18
- Boehringer Ingelheim (DE) . . . 19, 64, 68, 71
- Boehringer Ingelheim Austria GmbH 71
- Bristol-Myers Squibb (USA) 16
- Byondis BV (NL) 30
- C4 Therapeutics Inc. (USA) 18
- CANDOR Bioscience GmbH (DE)** 87
- Canify AS (DK) 66
- Cardior Pharmaceuticals GmbH (DE) 70
- CB21 Pharma Ltd. (CR) 53
- Celeris Therapeutics GmbH (A) 18, 19
- Celtic Renewables Ltd. (UK) 60
- China Biologics Products, Inc. 68
- Clariant (DE) 60
- co.don AG (DE) 70
- Coherus BioSciences Inc. (USA) 30
- Concept Heidelberg (DE) PharmaLab** . . . 36, 81
- Cowen Healthcare Royalty Partners (USA) 85
- CSL Ltd. (AUS) 68
- Dassault Systemes (UK) 12
- Deep Track Capital (USA) 26, 69
- DeuteRx LLC (USA) 18
- Dow Chemical Company (USA) 62
- Dunad Therapeutics (UK) 17, 18
- ECBF Management GmbH (DE)** . . . 82, 83, 86
- Elektrochaea GmbH (DE) 60
- Element Materials (DE)** 78
- EpiQMAx GmbH (DE) 34
- Eppendorf AG (DE)** 63
- Eppendorf Austria GmbH** 21
- EQT Partners AB (SE) 68
- EtheRNA immunotherapies NV (B) 68
- Evotec (Modena) Srl. (IT) 72
- Evotec SE (DE) 16, 18, 68, 72
- Excelya Group SAS (F)** 43, 44
- ExxonMobil (USA) 60
- F2G Ltd. (UK) 84
- FGK Clinical Research GmbH (DE)** 39
- Födergesellschaft IZB (DE)** 34, 35
- Forbion Capital Partners (NL) 67
- Forma Therapeutics (USA) 66
- Formycon AG (DE) 30, 74
- Frontier Medicines Corp. (USA) 18
- Fund+ (B) 68
- Galenica AG (CH) 84
- Genedata AG (CH) 84
- Genmab A/S (DK) 67
- GenScript Biotech (Netherlands) B.V.** 47
- Ginkgo Bioworks (USA) 59, 60
- GlaxoSmithKline (UK) 16
- Global Blood Therapeutics (USA) 66
- Global Energies (UK) 60
- Grail Inc. (USA) 12
- Grand Pharma Ltd. (UK) 68
- Grifols SA (ES) 68
- HBM Healthcare Investments (UK) 67
- i&i biotech Fund (LU) 19
- IDT Biologika GmbH (DE)** CP4
- illumina Inc. (USA) 12
- Immutep S.A. (F) 30
- Inflarx NV (DE) 31
- Informa Markets B.V.**
- CPhI 2022 (UK)** 79, 89
- INHECO GmbH (DE)** 49, 87
- Intercell AG (A) 31
- Invus S.A.S. (F) 67, 69
- Italfarmaco (IT) 73
- J&K Consulting GmbH (DE) 53
- Keensight Capital (F) 72
- Kinarus Therapeutics AG (CH) 30, 71
- Krajete GmbH (AT) 60, 62
- Lacer Pharmaceuticals (ES) 73
- Lanzatech Inc. (USA) 59, 60
- Magforce Nanotechnologies AG (GER) 70
- Marinomed Biotech AG (AT)** 33
- Merck & Co (USA) 17, 64
- Merck KGaA (DE) 30, 38, 68, 71
- Minaris Regenerative Medicine GmbH (DE)** 9
- Mitsui (JP) 60
- Moderna Inc. (USA) 39, 68
- Morningside Ventures (USA) 85
- Neosphere Biotechnologies GmbH (DE) 19, 20
- Neste Jacobs Oy (FI) 60, 73
- Novalis Life Sciences LLC 68
- Novartis AG (CH) 16, 64
- Novo Nordisk A/S (DK) 66, 85
- Novo Seeds (DK) 12
- Novozymes A/S (DK) 60, 68
- NRx Pharmaceuticals Inc. (USA) 22
- Oaktree Acquisition Corp. (USA) 67
- Octapharma AG (DE) 64, 68
- Oerth Bio (USA) 15
- Omega Fund USA) 68
- Opel Automobile GmbH (DE) 62
- Origo Biopharma SL (IT) 73
- Ottobock Healthcare (DE) 64
- Oxea GmbH (GER) 6
- Pace Ventures Enigma (DE) 19
- Patheon Pharmaceutical Serv. (USA)** . . . 46, 55
- Petroleum Group (GR) 73
- Pfizer (USA) 16, 30, 31, 64, 66, 73
- Phytonix (USA) 62
- PlasmidFactory GmbH & Co. KG (DE)** 19
- Plexium (USA) 18
- PMV (B) 68
- Polpharma Biologics (PL) 30, 74
- PPF Group (CR) 74
- Prima Biotech GmbH (DE) 30
- Proteovant Therapeutics (USA) 18
- Proxygen (A) 71
- PULSE Chaux-sur-Lausanne (CH)** 28, 29
- QLi5 therapeutics (DE) 20
- R42 Group (USA) 18
- Redmile Group (USA) 67
- Relief Therapeutics SA (CH) 22
- Rentschler Biopharma (DE)** 38, 40, 42, 45
- Richter-Helm BioLogics GmbH (DE)** 41
- Rigenerand Srl. (IT) 72
- Robur Fonder (SE) 67
- Roche AG (CH) 17, 30
- Sartorius SE (DE) 68
- Sartorius Stedim Biotech GmbH (CH) 68
- Shell (NL) 60
- Shimadzu Europa GmbH (DE)** CP2
- Shionogi (JP) 85
- Sincere Pharmaceutical Group (CN) 30
- Sino Biological Europe (DE)** 11, 87
- Sofinnova Partners (F) 12, 69
- Sotio a.s. (CR) 74
- Swiss Biotech Association (SBA)** 84, CP3
- Takeda Pharmaceuticals (JP) 64, 66, 68
- TCGX (USA) 26, 69
- Thermo Fisher Scientific (USA) 68
- Truffle Capital (FR) 69
- VALIDOGEN GmbH (AT)** 38
- Valneva (F/AT) 31
- Vattenfall (SE) 60
- Vector Biopharma AG (CH) 39, 54
- Veeva Systems Inc. (USA) 39
- Venrock Healthcare Capital (USA) 26, 69
- Ventria Bioscience (USA) 68
- Veristat International Ltd (UK)** 51
- Vetter Pharma-Fertigung GmbH (DE)** 31
- Vialis SA (CH) 31
- Vibalogs GmbH (DE)** 4, 5, 48, 49
- Vifor Pharma (CH) 84
- Vivebiotech S.L. (ES) 72
- Vividion Therapeutics (USA) 17
- Volkswagen AG (DE) 62
- VTU Technology GmbH (AT) 65
- Wacker Chemie AG (DE) 70
- Walleye Capital LLC (USA) 73
- Y-Science (FIN) 67
- YUMAB GmbH (DE)** 17
- ZAMBON Company S.p.a. (IT) 72
- Zelluna Immunotherapies AS (NO) 66
- Zeta Bio- und Verfahrenstechnik (AT) 65
- Zymergen Inc. (USA) 60

Save the date!

SWISS BIOTECH DAY

© Swiss Biotech Association

April 24-25, 2023
Congress Center Basel


As one of the leading biotechnology conferences, the Swiss Biotech Day has developed into a truly global networking day, attracting many international delegations.

What you can expect:

- › Meet 1,000+ senior experts from the life science industry
- › 70+ exhibitors and global village with international delegations from all over the world
- › Swiss Biotech Success Stories Awards
- › Innovative biotech start-ups and medium-sized biotech companies
- › Thematically focused panel discussions
- › Swiss Biotech Report 2023
- › Pre-scheduled one-to-one partnering meetings
- › General Assembly of the Swiss Biotech Association

Sign in on our website at
www.swissbiotechday.ch
and stay updated about any news.

Proudly presenting our first sponsors:



Media partners:



Organized by:



Advancing Biologics. Protecting Life.

**NEW
CAPACITIES**
in Drug Substance
and Fill-Finish
available



Dedicated to Contract Development and Manufacturing
of Clinical Trial Materials and Commercial Products:

- Cell & Gene Therapeutics
- Viral Vectors
- Oncolytic Viruses
- Vaccines



Development



Drug Substance
Manufacturing
up to BSL-3



Drug Product
Manufacturing



Labeling
& Packaging



Quality Control
& Analytics

Learn more about Partnering with IDT Biologika

IDT Biologika
Am Pharmapark
06861 Dessau-Rosslau
Germany

IDT Biologika Corporation
1405 Research Boulevard
Rockville, MD 20850
USA

www.idt-biologika.com
info@idt-biologika.com

